KR900011486A - 하이드로겔에 의해 작동되는 분배장치 - Google Patents

하이드로겔에 의해 작동되는 분배장치 Download PDF

Info

Publication number
KR900011486A
KR900011486A KR1019900000280A KR900000280A KR900011486A KR 900011486 A KR900011486 A KR 900011486A KR 1019900000280 A KR1019900000280 A KR 1019900000280A KR 900000280 A KR900000280 A KR 900000280A KR 900011486 A KR900011486 A KR 900011486A
Authority
KR
South Korea
Prior art keywords
layer
dispensing device
hydrogel
mixture
osmosis
Prior art date
Application number
KR1019900000280A
Other languages
English (en)
Other versions
KR920008702B1 (ko
Inventor
존 큐라톨로 윌리암
Original Assignee
윌리암 데이비스 헌
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리암 데이비스 헌, 화이자 인코포레이티드 filed Critical 윌리암 데이비스 헌
Publication of KR900011486A publication Critical patent/KR900011486A/ko
Application granted granted Critical
Publication of KR920008702B1 publication Critical patent/KR920008702B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

하이드로겔에 의해 작동되는 분배장치
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 정제 형태인, 본 발명장치(1)의 한 태양의 투시도이다, 제2도는 제1도에 나타내 장치(1)를 선2-2에 따라 절단한 횡단면도이다, 제3도는 장치(1)를 둘러싸고 있는 코팅(3)안에 2개의 층(6과7)을 포함하는 제1도에 나타낸 장치(1)를 선2-2에 따라 절단한 장치(1)의 또 다른 태챵의 횡단면도이다.

Claims (37)

  1. (a)하나 이상의 유익한 약물과 하이드로겔을 포함하는 혼합물과 (b) 상기 혼합물을 둘러싸고 있고, 다수의 기공을 함유한 코팅을 포함하는 분배장치.
  2. 제1항에 있어서, 상기 유익한 약물이 약제이고, 상기 하이드로겔이 폴리에틸렌 옥사이드이고, 상기 코팅이 셀룰로즈 아세테이트를 포함하는 분배장치.
  3. 제1항에 있어서, 상기 혼합물이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 상기 코팅이 적어도 하나의 구멍(hole)을 추가로 함유하는 분배장치.
  5. (a)하나 이상의 유익한 약물과 하이드로겔을 포함하는 혼합물과, (b)상기 혼합물을 둘러싸고 있고, 중합체와 하나 이상의 가공형성제(porosigens)를 함유한 코팅을 포함하는 분배장치.
  6. 제5항에 있어서, 상기 유익한 약물이 약제이고, 상기 하이드로겔이 폴리에틸렌 옥사이드이고, 상기 코팅 중합체가 셀룰로즈 아세테이트인 분배장치.
  7. 제5항 또는 제6항에 있어서, 상기 기공형성제가 하나 이상의 수용성 중합체인 분배장치.
  8. 제7항에 있어서, 상기 수용성 중합체가 하이드록시프로필 셀룰로즈, 폴리에틸렌 글리콜 및 폴리에틸렌 옥사이드로 구성된 그룹중에서 선택되는 분배장치.
  9. 제5항 또는 제6항에 있어서, 상기 기공형성제가 하나 이상의 수용성 중합체와 하나 이상의 무기염인 분배장치.
  10. 제5항 또는 제6항에 있어서, 상기 기공형성제가 하나 이상의 수용성 중합체와 하나 이상의 수용성 미립유기 화합물 및 그의 염인 분배장치.
  11. 제10항에 있어서, 상기 수용성 중합체가 폴리에틸렌 글리콜-600이고 상기 수용성 미립 유기화합물이 슈크로즈인 분배장치.
  12. 제5항 또는 제6항에 있어서, 상기 기공형성제가 하나 이상의 무기염 또는 하나이상의 수용성 미립 유기 화합물 및 그의 염인 분배장치.
  13. 제5항에 있어서, 상기 혼합물이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  14. 제5항에 있어서, 상기 코팅이 적어도 하나의 구멍을 추가로 함유하는 분배장치.
  15. (a)하나 이상의 유익한 약물과 하이드로겔의 혼합물을 포함하는 제1층, (b)상기 제1층에 인접해 있으며 제1층과 접촉하는 지대를 포함하는 하이드로겔을 함유한 제2층 및 (c)제1층과 제2층이 접촉하고 있는 상기 지대를 제외한 제1층과 제2층을 둘러싸고 있고, 상기 제1층에 인접한 구멍을 적어도 한개 함유한 코팅을 포함한 분배장치.
  16. 제15항에 있어서, 상기 제1층 또는 제2층이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  17. 제15항에 있어서, 상기 제1층과 제2층이 각각 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  18. 제15항에 있어서, 상기 코팅이 다수의 기공을 추가로 함유하는 분배장치.
  19. 제15항 내지 제18항중 어느 한 항에 있어서, 적어도 1개의 구멍을 함유하는 상기 코팅이 중합체와 하나 이상의 기공형성체를 포함하는 분배장치.
  20. (a)하나 이상의 유익한 약물과 하이드로겔의 혼합물을 포함하는 제1층, (b)상기 제1층에 인접해 있고 제1층과 접촉하는 지대를 포함하는, 하이드로겔을 함유한 제2층 및 (c)제1층과 제2층이 접촉하고 있는 상기 지대를 제외한 제1층과 제2층을 둘러싸고 있고, 중합체와 하나 이상의 가공형성제를 함유한 코팅을 포함하는 분배장치.
  21. 제20항에 있어서, 상기 제1층 또는 제2층이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  22. 제20항에 있어서, 상기 제1층 및 제2층이 각각 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  23. (a)하이드로겔을 포함하는 가장 안쪽의 층, (b)상기 가장 안쪽의 층에 인접하여 그 층을 둘러싸고 있고, 하나 이상의 유익한 약물과 하이그로겔의 혼합물을 포함하는 가장 바깥쪽의 층 및 (c) 상기 가장 바깥쪽의 층을 둘러싸고 있고, 다수의 기공을 함유한 코팅을 포함하는 분배장치.
  24. 제23항에 있어서, 상기 가장안쪽의 층 또는 가장 바깥쪽의 층이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  25. 제23항에 있어서, 상기 가장 안쪽의 층 및 가장 바깥쪽의 층이 각각 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  26. (a)하이드로겔을 포함하는 가장 안쪽의 층, (b)상기 가장 안쪽의 층에 인접하여 그 층을 둘러싸고 있고, 하나 이상의 유익한 약물과 하이드로겔의 혼합물을 포함하는 가장 바깥쪽의 층 및 (c) 상기 가장 바깥쪽의 층을 둘러싸고 있고, 중합체와 하나 이상의 기공형성제를 함유한 코팅을 포함하는 분배장치.
  27. 제26항에 있어서, 상기 가정 안쪽의 층 또는 가장 바깥쪽의 층이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  28. 제26항에 있어서, 상기 가정 안쪽의 층 및 가장 바깥쪽의 층이 각각 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  29. (a) 하나 이상의 유익한 약물과 하이드로겔을 포함하는 혼합물 및 (b)상기 혼합물을 둘러싸고 있고, 하나 이상의 구멍을 함유한 코팅을 포함하는 분배장치.
  30. 제29항에 있어서, 상기 혼합물이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  31. (a)하나 이상의 유익한 약물과 하이드로겔의 혼합물을 포함하는 제1층, (b)상기 제1층에 인접해 있고 제1층과 접촉하는 있는 지대를 포함하는 하이드로겔을 함유한 제2층 및 (c)제1층과 제2층이 접촉하고 있는 상기 지대를 제외한 제1층과 제2층을 둘러싸고 있고, 다수의 기공을 함유한 코팅을 포함하는 분배장치.
  32. 제31항에 있어서, 상기 제1층 또는 제2층이 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  33. 제31항에 있어서, 상기 제1층과 2층이 각각 삼투에 효과적인 용질을 추가로 포함하는 분배장치.
  34. 제1항 내지 제33항중 어느 한 항에 청구된 장치를 유용한 환경에 놓음을 포함하는 하나 이상의 유익한 약물을 유용한 환경에 조절하면서 전달하는 방법.
  35. 장치내의 유익한 약물이 약제인 제1항, 5항, 15항, 20항, 23항, 26항, 29항, 또는 31항중 어느 한 항에 청구된 장치를 동물에 투여함을 포함하는 동물에게 약제를 조절하면서 전달하는 방법.
  36. 수용성 벽과 하나 이상의 제26항의 장치를 포함하는 캅셀.
  37. 장치내의 유익한 약물이 약제인 제36항에 청구된 장치를 동물에게 투여함을 포함하는, 동물에게 약제를 조절하면서 전달하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900000280A 1989-01-12 1990-01-11 하이드로겔에 의해 작동되는 분배 장치 KR920008702B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29646489A 1989-01-12 1989-01-12
US296,464 1989-01-12

Publications (2)

Publication Number Publication Date
KR900011486A true KR900011486A (ko) 1990-08-01
KR920008702B1 KR920008702B1 (ko) 1992-10-08

Family

ID=23142114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900000280A KR920008702B1 (ko) 1989-01-12 1990-01-11 하이드로겔에 의해 작동되는 분배 장치

Country Status (19)

Country Link
US (2) US5516527A (ko)
EP (1) EP0378404B1 (ko)
JP (1) JPH07119171B2 (ko)
KR (1) KR920008702B1 (ko)
AT (1) ATE110578T1 (ko)
AU (1) AU615129B2 (ko)
CA (1) CA2007463C (ko)
DE (1) DE69011878T2 (ko)
DK (1) DK0378404T3 (ko)
ES (1) ES2058775T3 (ko)
FI (1) FI900153A (ko)
HU (1) HUT54038A (ko)
IE (1) IE64201B1 (ko)
IL (1) IL92966A (ko)
MY (1) MY105761A (ko)
NO (1) NO900151L (ko)
NZ (1) NZ232078A (ko)
PT (1) PT92838B (ko)
ZA (1) ZA90197B (ko)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
EP0607321A1 (en) * 1991-10-10 1994-07-27 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
PL171110B1 (pl) * 1991-12-27 1997-03-28 Merck & Co Inc Sposób wytwarzania tabletki do kontrolowanego wytwarzania i uwalniania in situ dyspersji zawierajacej lek PL PL PL
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
ZA935569B (en) * 1992-07-31 1994-04-12 Daratech Pty Ltd Controlled release implants
AU682827B2 (en) * 1992-09-18 1997-10-23 Astellas Pharma Inc. Sustained-release hydrogel preparation
JPH06256166A (ja) * 1993-01-06 1994-09-13 ▲寛▼治 ▲高▼田 薬物放出制御製剤
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
WO1995030422A1 (en) * 1994-05-06 1995-11-16 Pfizer Inc. Controlled-release dosage forms of azithromycin
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
CA2269707C (en) * 1996-10-25 2005-08-16 Edward M. Rudnic Soluble form osmotic dose delivery system
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6228392B1 (en) * 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
US6251432B1 (en) * 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
EP1242055B1 (en) * 1999-12-23 2008-04-23 Pfizer Products Inc. Hydrogel-driven drug dosage form
EP1738749A1 (en) 1999-12-23 2007-01-03 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
US6296993B1 (en) 2000-06-13 2001-10-02 Eastman Kodak Company Method of providing digitized photographic image
US6361225B1 (en) 2000-06-13 2002-03-26 Eastman Kodak Company Apparatus for providing a photochemical reaction
US6309810B1 (en) 2000-06-13 2001-10-30 Eastman Kodak Company Photochemical delivery article and method of use
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US6770721B1 (en) * 2000-11-02 2004-08-03 Surface Logix, Inc. Polymer gel contact masks and methods and molds for making same
JPWO2002064114A1 (ja) * 2001-02-15 2004-06-10 株式会社三和化学研究所 新規眼科用組成物
EP1372614A4 (en) * 2001-03-16 2007-10-31 Andrx Pharmaceuticals Llc SULPHONYL UREA FORMULATION WITH CONTROLLED RELEASE
US20030008007A1 (en) * 2001-04-23 2003-01-09 Jose Gutierrez-Rocca Release pharmaceutical construct for gastric retention
CA2461354C (en) * 2001-09-28 2010-04-27 Mcneil-Ppc, Inc. Fondant-based pharmaceutical composition
JP2005528330A (ja) * 2001-11-30 2005-09-22 ファイザー・プロダクツ・インク 5,7,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11)3,5,7,9−ペンタエンの医薬組成物
CA2473991C (en) 2002-02-01 2009-09-15 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
CA2484874A1 (en) * 2002-05-06 2003-11-13 Ranbaxy Laboratories Limited Monocompartment osmotic controlled drug delivery system
AU2003256844A1 (en) * 2002-07-29 2004-02-16 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
UY28326A1 (es) * 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
CA2530136C (en) 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
WO2005000268A2 (en) 2003-06-26 2005-01-06 Control Delivery Systems, Inc. Bioerodible sustained release drug delivery systems
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
NZ552793A (en) * 2004-08-02 2011-01-28 Samyang Corp Biodegradable multi-block polymeric composition capable of sol-gel transition
WO2006054152A1 (en) * 2004-11-22 2006-05-26 Ranbaxy Laboratories Limited Monocompartment osmotic-controlled delivery system of doxazosin
JP2007070344A (ja) * 2005-08-11 2007-03-22 Tsukioka:Kk 内服薬
CA2949643C (en) * 2005-09-27 2018-05-15 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
NZ543314A (en) * 2005-10-28 2007-08-31 Interag A delivery system where the driving substance contains the active component
AP3071A (en) 2005-11-28 2014-12-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the makingand use thereof
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US7838716B2 (en) * 2006-08-11 2010-11-23 Feg Holdings, Llc High speed swelling, pressure exerting hemostatic device
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8812637B2 (en) * 2006-11-28 2014-08-19 International Business Machines Corporation Aggregation of multiple media streams to a user
US20080127272A1 (en) * 2006-11-28 2008-05-29 Brian John Cragun Aggregation of Multiple Media Streams to a User
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
CN101854933A (zh) 2007-09-10 2010-10-06 钙医学公司 调节细胞内钙的化合物
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
DK2421901T3 (en) 2009-04-24 2016-01-11 Tissue Tech Inc Compositions comprising HC-HA complex, and methods of use thereof
SG176785A1 (en) 2009-06-16 2012-01-30 Pfizer Dosage forms of apixaban
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
AU2011230778A1 (en) 2010-03-23 2012-08-02 Aska Pharmaceutical Co., Ltd. Solid preparation
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
WO2011139765A2 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2011261185A1 (en) 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
BR112012033341B1 (pt) 2010-06-30 2022-08-23 Cyclerion Therapeutics, Inc Estimulantes de sgc
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
JP5878546B2 (ja) 2010-11-09 2016-03-08 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激剤
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
HUE049690T2 (hu) 2012-01-06 2020-10-28 Lundbeck La Jolla Research Center Inc Karbamátvegyületek és eljárások azok elõállítására és alkalmazására
US9046085B2 (en) * 2012-03-14 2015-06-02 Eden Medical, Inc. Miniature pumps
WO2013155422A1 (en) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
US9540382B2 (en) 2012-06-04 2017-01-10 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
JP2015528001A (ja) 2012-07-11 2015-09-24 ティッシュテック,インク. Hc−ha/ptx3複合体を含む組成物およびその使用方法
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9416141B2 (en) 2012-09-28 2016-08-16 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
US10172791B2 (en) * 2013-03-14 2019-01-08 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
PT2970243T (pt) 2013-03-15 2020-03-05 Cyclerion Therapeutics Inc Estimuladores de sgc
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN104971414A (zh) * 2014-04-01 2015-10-14 黄震山 药物缓释器
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP6624616B2 (ja) 2014-09-17 2019-12-25 サイクレリオン・セラピューティクス,インコーポレーテッド sGC刺激剤
AU2015317823A1 (en) 2014-09-17 2017-03-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
KR102557184B1 (ko) 2015-02-06 2023-07-18 유니버시티 오브 워싱톤 감각 유모 세포 사멸을 예방 또는 치료하기 위한 화합물 및 방법
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
EA039121B1 (ru) 2015-02-27 2021-12-07 Куртана Фармасьютикалс, Инк. ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
RS65234B1 (sr) 2015-03-03 2024-03-29 Pharmacyclics Llc Farmaceutske formulacije inhibitora brutonove tirozin kinaze
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
EP3297645A4 (en) 2015-05-20 2018-12-12 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
BR112018003836A2 (pt) 2015-08-31 2018-12-04 Pharmacyclics Llc combinações de inibidor de btk para tratar mieloma múltiplo
FI3827838T3 (fi) 2015-12-16 2023-06-19 Walter & Eliza Hall Inst Medical Res Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa
JP7109365B2 (ja) 2016-01-19 2022-07-29 ヤンセン ファーマシューティカ エヌ.ベー. Btk阻害剤を含む製剤/組成物
US20190290650A1 (en) 2016-01-19 2019-09-26 Janssen Pharmaceutic Nv Formulations/compositions comprising a btk inhibitor
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
EP3442538A4 (en) 2016-04-04 2019-11-20 Sinopia Biosciences, Inc. TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
JP2019524747A (ja) 2016-07-18 2019-09-05 アースローシ セラピューティクス,インク. 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法
CA3035123A1 (en) 2016-08-26 2018-03-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
RS62256B1 (sr) 2016-09-02 2021-09-30 Cyclerion Therapeutics Inc Fuzionisani biciklični sgc stimulatori
SG10202104876SA (en) 2016-11-08 2021-06-29 Cyclerion Therapeutics Inc Sgc stimulators
EA201991147A1 (ru) 2016-11-08 2019-11-29 ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
EA201991086A1 (ru) 2016-11-16 2019-11-29 Кристаллические формы ингибитора magl
WO2019046731A1 (en) 2017-09-01 2019-03-07 University Of Washington CRYSTALLINE FORMS OF COMPOUNDS FOR PREVENTING OR TREATING DEATH OF SENSORY CILIC CELLS
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
BR112021011578A2 (pt) 2018-12-31 2021-08-31 Biomea Fusion, Llc Inibidores irreversíveis de interação menina-mll
US20220265630A1 (en) 2019-03-15 2022-08-25 Unicycive Therapeutics Inc. Nicorandil derivatives
EP4139288A1 (en) 2020-04-21 2023-03-01 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
EP4263542A1 (en) 2020-12-16 2023-10-25 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
CA3218884A1 (en) 2021-05-11 2022-11-17 David Nutt Therapeutic aminoindane compounds and compositions
AU2022283967A1 (en) 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
US20230120115A1 (en) 2021-08-11 2023-04-20 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
TW202313004A (zh) 2021-08-20 2023-04-01 美商拜歐米富士恩股份有限公司 Menin-mll相互作用之不可逆抑制劑的結晶形式
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024011142A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4180073A (en) * 1977-08-29 1979-12-25 Alza Corporation Device for delivering drug to biological environment
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4320759A (en) * 1980-04-28 1982-03-23 Alza Corporation Dispenser with diffuser
US4350271A (en) * 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4663286A (en) * 1984-02-13 1987-05-05 Damon Biotech, Inc. Encapsulation of materials
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4772474A (en) * 1985-08-09 1988-09-20 Alza Corporation Dispenser with internal arrangement of lamina means for dispensing beneficial agent
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
CA1266827A (en) * 1984-06-20 1990-03-20 Merck & Co., Inc. Controlled porosity osmotic pump
US4608048A (en) * 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
CA1242394A (en) * 1985-03-07 1988-09-27 Neil B. Graham Controlled release device
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
ES2022454B3 (es) * 1986-06-17 1991-12-01 Recordati Ind Chimica E Farm S P A Sistema terapeutico para la liberacion controlada de drogas.
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3629994A1 (de) * 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices

Also Published As

Publication number Publication date
IE64201B1 (en) 1995-07-12
AU4787790A (en) 1990-07-19
ATE110578T1 (de) 1994-09-15
FI900153A (fi) 1990-07-13
JPH07119171B2 (ja) 1995-12-20
ZA90197B (en) 1991-07-31
HUT54038A (en) 1991-01-28
NO900151D0 (no) 1990-01-11
IL92966A (en) 1995-07-31
IE900104L (en) 1990-07-12
CA2007463A1 (en) 1990-07-12
US5516527A (en) 1996-05-14
US5792471A (en) 1998-08-11
ES2058775T3 (es) 1994-11-01
DK0378404T3 (da) 1994-10-03
DE69011878T2 (de) 1994-12-15
KR920008702B1 (ko) 1992-10-08
PT92838A (pt) 1990-07-31
AU615129B2 (en) 1991-09-19
EP0378404A3 (en) 1990-10-03
CA2007463C (en) 1995-01-17
EP0378404A2 (en) 1990-07-18
FI900153A0 (fi) 1990-01-11
DE69011878D1 (de) 1994-10-06
HU900108D0 (en) 1990-03-28
JPH02229110A (ja) 1990-09-11
PT92838B (pt) 1996-02-29
MY105761A (en) 1995-01-30
NO900151L (no) 1990-07-13
EP0378404B1 (en) 1994-08-31
IL92966A0 (en) 1990-09-17
NZ232078A (en) 1991-02-26

Similar Documents

Publication Publication Date Title
KR900011486A (ko) 하이드로겔에 의해 작동되는 분배장치
ES2075444T3 (es) Sistema de dosificado osmotico para la administracion de un farmaco liquido.
KR880002502A (ko) 산에 민감한 유익한 약제의 투여용 제형(劑形)
SE9102072D0 (sv) Oral, fast, farmaceutisk doseringsform med styrd frisaettning
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
DK136186A (da) Laegemiddelbaerer
NO891680D0 (no) Osmotisk kontinuerlig avgivende oralt avgivelsessystem inneholdende et farmasoeytisk akseptabelt aktivt middel som har forbedrede kjernemembran-adhesjonsegenskaper.
DE60005819D1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
DK469989D0 (da) Farmaceutisk praeparat
SE9402431D0 (sv) New tablet formulation
ITMI922192A1 (it) Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
ES2097787T3 (es) Composicion farmaceutica para la administracion rectal de principios activos que presenta una accion de medicacion prevalentemente topica a nivel del colon.
CA2398893A1 (en) Improvements in and relating to controlling drug delivery apparatus
PT98802A (pt) Processo para a preparacao dum dispositivo osmotico com a forma de dosagem unitaria para a administracao de farmacos com velocidade de libertacao programada
DE769938T1 (de) Mehrschichtige Kapseln mit einer Siliconharzfüllung
ES2051881T3 (es) Procedimiento de preparacion de un formulacion farmaceutica de liberacion prolongada.
DE69940673D1 (de) Orales system zur verabreichung von gepulsten dosen eines arzneistoffs
DE69309540T3 (de) Orale Arzneimittel mit kolonspezifischer Freisetzung
IT8322832A0 (it) Dispositivo per la somministrazione controllata di farmaci.
ATE63059T1 (de) Vorrichtung mit zwei schichten zur freisetzung von arzneimitteln.
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
AR036838A1 (es) Comprimido de varias capas de liberacion controlada, uso del mismo para la fabricacion de un medicamento util en el tratamiento de la fibromialgia y composicion farmaceutica que lo comprende.
ES2113985T3 (es) Material de recubrimiento para formas medicamentosas de administracion oral.
ATE59551T1 (de) Feste orale arzneiformen mit gestaffelter wirkung zur verabreichung von wirkstoffen mit geschwuere erzeugender nebenwirkung.
JO1881B1 (en) Formula II for multi unit disc calibration

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021002

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee